Publication: Predictive factors for the efficacy of Er:YAG laser treatment of urinary incontinence
| dc.contributor.author | İNAN, DENİZ | |
| dc.contributor.authors | Erel, C. Tamer; Inan, Deniz; Mut, Aysegul | |
| dc.date.accessioned | 2022-03-12T22:41:59Z | |
| dc.date.accessioned | 2026-01-11T06:58:42Z | |
| dc.date.available | 2022-03-12T22:41:59Z | |
| dc.date.issued | 2020 | |
| dc.description.abstract | Objectives: To determine the efficacy and predictive factors for the success of Er:YAG laser treatment in patients with urinary incontinence (UI). Methods: Eighty-two patients with UI were treated by Er:YAG laser in this cohort study. The patients were evaluated by ICIQ-SF and KHQ-UI before and after the procedure. Improvement was categorized as: none (0-25%), mild (26-50%), moderate (51-75%), or high (76-100%). The duration of the treatment effect was evaluated at follow-up in relation to maximum improvement time (MIT) and total improvement time (TIT). Results: Forty-two patients were determined to have SUI and 40 patients MUI. The mean ISIQ-SF and KHQ-UI scores significantly improved after the procedure (p < 0.0001). The SUI patients responded to the laser treatment significantly better (p < 0.008). Younger women had significantly better results (p < 0.008), while premenopausal women (p < 0.032) and women in the early postmenopausal years (p < 0.032) also saw a positive response to the Er:YAG laser treatment. Women with a lower BMI had greater improvement (p < 0.011). The total laser energy expenditure during the sessions may also be a predictive parameter for the success of Er:YAG laser treatment of UI (p = 0.059). MIT and TIT were significantly longer among the patients in the high-improvement group. Conclusion: Er:YAG laser treatment of the symptoms of UI, especially SUI, is more efficacious and of longer duration for younger, premenopausal or early postmenopausal women with normal BMI. | |
| dc.identifier.doi | 10.1016/j.maturitas.2019.11.003 | |
| dc.identifier.eissn | 1873-4111 | |
| dc.identifier.issn | 0378-5122 | |
| dc.identifier.pubmed | 31883657 | |
| dc.identifier.uri | https://hdl.handle.net/11424/236190 | |
| dc.identifier.wos | WOS:000508738300001 | |
| dc.language.iso | eng | |
| dc.publisher | ELSEVIER IRELAND LTD | |
| dc.relation.ispartof | MATURITAS | |
| dc.rights | info:eu-repo/semantics/closedAccess | |
| dc.subject | Stress urinary incontinence | |
| dc.subject | Er:YAG laser | |
| dc.subject | Menopause | |
| dc.subject | BMI | |
| dc.subject | Age | |
| dc.subject | ERBIUM-YAG LASER | |
| dc.subject | SHORT-TERM EFFICACY | |
| dc.subject | GENITOURINARY SYNDROME | |
| dc.subject | SEXUAL FUNCTION | |
| dc.subject | WOMEN | |
| dc.subject | MENOPAUSE | |
| dc.subject | SYMPTOMS | |
| dc.subject | WEIGHT | |
| dc.title | Predictive factors for the efficacy of Er:YAG laser treatment of urinary incontinence | |
| dc.type | article | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | 6 | |
| oaire.citation.startPage | 1 | |
| oaire.citation.title | MATURITAS | |
| oaire.citation.volume | 132 |
